Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Sep 05, 2025
- Pharmaceuticals
- R&D
Roche’s Announcement Regarding Vabysmo (Presentation of New Long-Term Data in Neovascular or “Wet” Age-related Macular Degeneration)
TOKYO, September 5, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release today, regarding Vabysmo® (faricimab) of 4-year data from a Phase III clinical trial (AVONELLE-X) in neovascular or “wet” age-related macular degeneration (nAMD) and one-year data from the Phase IIIb/IV clinical trial (SALWEEN) in Asian patients with polypoidal choroidal vasculopathy (PCV) among nAMD. The detailed data were presented at the 25th European Society of Retina Specialists (EURETINA) Congress on September 5, 2025.
Please refer to the link below for details of the press release:
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)
https://www.roche.com/media/releases/med-cor-2025-09-05
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp